Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Some patients reluctantly shifted to save money while others have appealed for coverage of Zepbound after having experienced ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Novo Nordisk A/S's Wegovy, a semiglutide injectable medicine, is now the primary weight loss drug offered on CVS's standard formulary, a list of medications an insurance plan covers. The news was not ...

The healthcare sector, including managed-care firms and drug powerhouses, is vastly underperforming the S&P 500 index. Here ...

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay programs at $499 monthly ...

Eli Lilly's stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound. CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo ...

Eli Lilly on Thursday downplayed CVS Health’s decision to drop the company’s obesity drug Zepbound from some lists of medicines it covers for reimbursement, but shares of the drugmaker still ...

CVS Health on Thursday said it will significantly expand access to the blockbuster weight loss drug Wegovy for patients covered by its pharmacy benefit manager, Caremark. Starting July 1, Caremark ...

Goldman Sachs cuts Eli Lilly's price target to $883, citing PBM-related uncertainty after CVS dropped Zepbound. BofA keeps $1,000 price target, saying Zepbound remains superior and CVS move is not ...

CVS Health selected former Eli Lilly CFO Derica Rice to serve as the president of its pharmacy benefit management division, CVS Caremark, according to The Wall Street Journal. Effective March 30 ...